SOURCE-LINKED STUDY SUMMARY
Phase 2 study of zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies (DLB).
What was studied?
A double-blind phase 2 study tested zervimesine safety and exploratory efficacy in Lewy body dementia.
What changed?
Exploratory outcomes showed favorable trends. Adverse-event discontinuations were 4.5% with 100 mg, 16.3% with 300 mg and 4.8% with placebo.
Who was studied?
130 randomized adults aged 50–85 with probable mild-to-moderate Lewy body dementia; 109 completed the study.
Studied exposure
Zervimesine 100 mg, 300 mg or placebo over 26 weeks.
What remains uncertain?
Exploratory efficacy requires larger confirmatory trials. Findings do not establish dementia reversal, Alzheimer’s efficacy or healthy-person cognitive enhancement.
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1002/alz.71004